Literature DB >> 31015243

Pyoderma gangrenosum-like lesion secondary to methylenetetrahydrofolate reductase mutation: an unusual presentation of a rare disease.

Yana Turkowski1, Syed Razvi2, Abdul Razzaque Ahmed3,4.   

Abstract

Pyoderma gangrenosum (PG)-like ulcerations are a rare clinical manifestation of methylenetetrahydrofolate reductase (MTHFR) mutation. We describe a patient considered to have PG who was treated with long-term high doses of systemic corticosteroids and multiple immunosuppressive agents for several years. In spite of this continuous aggressive therapy, the lesions did not improve but continued to get worse. She developed many significant and catastrophic side effects to them. When referred to our dermatology centre, on investigation, it was discovered that she has an MTHFR mutation. It seemed reasonable to presume that PG-like lesions were related to it. Treatment with a biologically active form of folate-[6S]-5-MTHF-with vitamins B6 and B12 was initiated. It was considered to be beneficial and capable of reducing hyperhomocysteinaemia and endothelial damage consequent from it. Since the institution of this treatment, the patient has begun to show very gradual but slow and incremental improvement. © BMJ Publishing Group Limited 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  dermatology; genetics

Mesh:

Substances:

Year:  2019        PMID: 31015243      PMCID: PMC6505980          DOI: 10.1136/bcr-2018-228403

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

Review 1.  Diagnosis and treatment of pyoderma gangrenosum.

Authors:  Trevor Brooklyn; Giles Dunnill; Chris Probert
Journal:  BMJ       Date:  2006-07-22

2.  Genetic risk factors of chronic venous leg ulceration: Can molecular screening aid in the prevention of chronic venous insufficiency complications?

Authors:  Tomasz Grzela; Agata Bialoszewska
Journal:  Mol Med Rep       Date:  2010 Mar-Apr       Impact factor: 2.952

3.  Skin ulcers mimicking pyoderma gangrenosum in a patient with MTHFR polymorphism.

Authors:  Belén Rubio-González; María Castellanos-González; Victoria Alegría-Landa; María del Mar Burgués-Calderón; Carlos Zarco-Olivo; Francisco Vanaclocha-Sebastián
Journal:  J Am Acad Dermatol       Date:  2012-12       Impact factor: 11.527

4.  The use of B vitamins for cutaneous ulcerations mimicking pyoderma gangrenosum in patients with MTHFR polymorphism.

Authors:  Douglas New; Philip Eaton; Al Knable; Jeffrey P Callen
Journal:  Arch Dermatol       Date:  2011-04

Review 5.  Biochemistry of homocysteine in health and diseases.

Authors:  S Ramakrishnan; K N Sulochana; S Lakshmi; R Selvi; N Angayarkanni
Journal:  Indian J Biochem Biophys       Date:  2006-10       Impact factor: 1.918

Review 6.  Pyoderma gangrenosum: pathogenetic oriented treatment approaches.

Authors:  Uwe Wollina; Georgi Tchernev
Journal:  Wien Med Wochenschr       Date:  2014-06-05

Review 7.  Methylenetetrahydrofolate reductase: biochemical characterization and medical significance.

Authors:  Elizabeth E Trimmer
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

8.  [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C-->T polymorphism of methylenetetrahydrofolate reductase.

Authors:  R Prinz-Langenohl; S Brämswig; O Tobolski; Y M Smulders; D E C Smith; P M Finglas; K Pietrzik
Journal:  Br J Pharmacol       Date:  2009-12       Impact factor: 8.739

9.  Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women.

Authors:  Yvonne Lamers; Reinhild Prinz-Langenohl; Rudolf Moser; Klaus Pietrzik
Journal:  Am J Clin Nutr       Date:  2004-03       Impact factor: 7.045

10.  Importance of Accurate Diagnosis in Pyoderma Gangrenosum.

Authors:  Yoon Soo Kim; Han Kyeol Kim; Yea Sik Han
Journal:  Arch Craniofac Surg       Date:  2014-12-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.